Half-life extension using serum albumin-binding DARPin® domains

• Published in: Protein engineering, design and selection Vol. 30; no. 9; pp. 583 - 591
• Main Authors: Steiner, Daniel, Merz, Frieder W, Sonderegger, Ivo, Gulotti-Georgieva, Maya, Villemagne, Denis, Phillips, Douglas J, Forrer, Patrik, Stumpp, Michael T, Zitt, Christof, Binz, H Kaspar
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01-09-2017
• Subjects: Animals; Ankyrin Repeat; Cloning, Molecular; Escherichia coli - genetics; Escherichia coli - metabolism; Gene Expression; Genetic Vectors - chemistry; Genetic Vectors - metabolism; Half-Life; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Protein Binding; Protein Stability; Recombinant Fusion Proteins - biosynthesis; Recombinant Fusion Proteins - genetics; Recombinant Fusion Proteins - pharmacokinetics; Serum Albumin - genetics; Serum Albumin - metabolism; pharmacokinetics; serum albumin; half-life; designed ankyrin repeat protein
• ISSN: 1741-0126; 1741-0134
• DOI: 10.1093/protein/gzx022

Abstract
A long systemic half-life is key for therapeutic proteins. To that end we have generated serum albumin-binding designed ankyrin repeat domains. These domains bind serum albumin of different species with nanomolar affinities, and have significantly improved pharmacokinetic properties both in mouse and cynomolgus monkey compared to non-serum albumin-binding DARPin® domains. In addition, they exhibit high thermal stability and long storage stability, which is an essential feature for their use in drug development. Covalently linking a serum albumin-binding DARPin® domain to domains with other target specificities results in improvements of multiple orders of magnitude in exposure and terminal half-life, both in mouse and cynomolgus monkey. Pharmacokinetic assessment of such constructs revealed terminal half-life values ranging from 27 h to 80 h in mouse, and from 2.6 days to 20 days in cynomolgus monkey. Extrapolation by allometric scaling on these findings suggests terminal half-life values of 5-50 days in human, indicating that pharmacokinetic properties in the range of monoclonal antibodies can be achieved with DARPin® drug candidates. Such serum albumin-binding DARPin® domains are thus valuable tools for the generation of multi-functional drugs with an extended in vivo half-life.